Phase I Study of Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2019
At a glance
- Drugs GL ONC1 (Primary)
- Indications Carcinoma; Malignant pleural effusion; Mesothelioma; Non-small cell lung cancer
- Focus Adverse reactions
- 17 Jan 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 17 Jan 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.
- 31 Aug 2018 Biomarkers information updated